The first cellular immunotherapy stock, Immunotech Biopharm Ltd. ("Yongtai Bio" or "Company", stock code: 6978), was officially listed for trading on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") this morning. As the company's financial public relations consultant team, Porda Havas participated in media guidance and interviews during the company's listing process, and assisted the company to successfully list in Hong Kong.